Teva's laquinimod fails Phase III RRMS trial

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and partner Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg laquinimod (SAIK-MS) missed the primary endpoint in the Phase III CONCERTO trial to treat relapsing-remitting multiple sclerosis (RRMS). Teva said it has no plans to further develop laquinimod to treat RRMS.

Laquinimod missed the primary endpoint of improving time to confirmed disability progression (CDP) after ≥3 months vs. placebo (HR=0.937; p=0.7057). CDP was defined as a ≥0.5- or ≥1-point improvement in Kurtzke’s Expanded Disability Status Scale (EDSS) score in patients with baseline EDSS scores of 5.5 or ≤5 points, respectively...